Calcimar Benefits, Uses, and Side Effects Explained
Table of Contents
Calcimar is a medication containing the synthetic hormone calcitonin, which is derived from salmon. It is manufactured by Sanofi Aventis and is primarily used in the treatment of various bone disorders and calcium-related conditions. Calcimar plays a crucial role in regulating calcium levels in the body and promoting bone health.
Medical Uses of Calcimar
Calcimar is approved for the following medical uses:
- Treatment of Paget’s disease , a chronic bone disorder that disrupts the normal cycle of bone remodeling.
- Management of postmenopausal osteoporosis, a condition characterized by decreased bone mass and increased risk of fractures in women after menopause.
- Reduction of high blood calcium levels (hypercalcemia), which can occur due to various underlying medical conditions.
Mechanism of Action
Calcimar is a synthetic form of the hormone calcitonin, which is naturally produced by the thyroid gland. Calcitonin plays a crucial role in regulating calcium and phosphate metabolism in the body. When administered, Calcimar helps lower blood calcium levels by inhibiting the resorption of calcium from bones and increasing calcium excretion through the kidneys.
Formulations and Administration
Calcimar is available in the following formulations:
- Injection : Calcimar is available as a sterile solution for injection, available in both intravenous and subcutaneous forms. It is typically supplied in multidose vials containing either 200 IU/mL or 400 IU/2 mL of calcitonin salmon.
- Intranasal: An intranasal formulation of Calcimar, known as Miacalcin, is also available for the treatment of postmenopausal osteoporosis.
Side Effects and Adverse Reactions
Like any medication, Calcimar may cause side effects in some patients. Common side effects include nausea, inflammation or redness at the injection site, and flushing of the face and hands. More severe side effects, although rare, can also occur.
Drug Interactions
Patients should inform their healthcare provider about all medications they are taking, as Calcimar may interact with certain drugs. Potential interactions should be carefully evaluated and monitored by a healthcare professional.
Clinical Trials and Research
Calcimar has been the subject of numerous clinical trials and ongoing research studies to evaluate its efficacy, safety, and potential new applications. The results of these studies continue to shape the understanding and use of this medication.
Regulatory Status
Calcimar, with the active ingredient calcitonin salmon, was approved by the U.S. Food and Drug Administration (FDA) in 1975 under the New Drug Application (NDA) 017769. It has also received regulatory approvals in various other countries, including Canada and across Europe.
Brand and Manufacturer Information
Calcimar is a brand name product manufactured by Sanofi Aventis, a multinational pharmaceutical company headquartered in France. Sanofi Aventis acquired Rhône-Poulenc Rorer (RPR), the original developer of Calcimar, in 1999.
Patient Information
Patients receiving Calcimar should follow their healthcare provider’s instructions carefully regarding dosage, administration, and monitoring. It is important to report any side effects or concerns to their healthcare team. Proper injection techniques and self-administration procedures should be reviewed with patients to ensure safe and effective use of Calcimar.
Healthcare Professional Information
Healthcare professionals should refer to the detailed product monograph and prescribing guidelines when administering or recommending Calcimar. Careful evaluation of the patient’s medical history, concurrent medications, and potential drug interactions is essential. Regular monitoring of calcium levels, bone density, and overall response to treatment is recommended.
